FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback